Biochemical Assay Core

生化检测核心

• 批准号: 10513868
• 负责人: John Damon Chodera
• 金额: $ 131.53万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-16 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10513868
• 关键词: Biochemical; Biological Assay; Structure

A main driver of drug discovery and medicinal chemistry optimization projects is rapid access to quality biochemical activity data of a large number of compounds. Such data facilitates the elucidation of structureactivity relationships and drives decision making in the design-make-test cycle. The Biochemical Assay Core will be in charge of providing the ASAP Center rapid and extensive biochemical assays for the target portfolio. The Core will establish a robust pipeline with the most rigorous assay acceptance criteria. The iterative nature of the activities means that testing of compounds will be performed over an extended time period. Clear protocols and controls are required to enable a high standard of reproducibility. Documentation and quality control will enable the efficient use of resources as compounds and assays are transferred between the interacting groups in the consortium. Access to industry-level automated assays, screening and compound collections provided by the Biochemical Assay Core will be a force multiplier for the ASAP Center in the discovery and development of antiviral drugs.

药物发现和药物化学优化项目的主要驱动力是快速获得质量 大量化合物的生化活性数据。这样的数据有助于阐明结构性 关系并驱动在设计策划周期中的决策。生化测定核心将 负责为目标投资组合提供ASAP中心快速而广泛的生化测定。这 核心将建立强大的管道，并具有最严格的测定标准。迭代性的本质 活动意味着化合物的测试将在延长的时间段内进行。清晰的协议和 需要控件以实现高标准的可重复性标准。文档和质量控制将启用 资源作为化合物和测定的有效利用在交互组之间转移 财团。访问行业级的自动化测定，筛选和化合物收集 生化测定核心将成为ASAP中心的力量乘数 抗病毒药物。